Bristol Myers Squibb Reveals Opdivo Results for Lung Cancer at ASCO 2024
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb (NYSE:BMY) announced positive results from three studies on Opdivo for non-small cell lung cancer at the ASCO 2024 Annual Meeting.
June 03, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb announced positive results from three studies on Opdivo for non-small cell lung cancer at the ASCO 2024 Annual Meeting.
The positive results from the CheckMate studies on Opdivo for NSCLC are likely to boost investor confidence and potentially drive up BMY's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100